#1 Clinical Trials Search in Europe

Motixafortide

Motixafortide, also known as BL-8040, is a promising drug being studied in various clinical trials for its potential in stem cell mobilization and cancer treatment. This article explores the ongoing research on Motixafortide, focusing on its use in conditions such as sickle cell disease, multiple myeloma, and pancreatic cancer. The trials aim to evaluate the drug’s safety, efficacy, and potential benefits when combined with other treatments.

Table of Contents

What is Motixafortide?

Motixafortide, also known as BL-8040 or APHEXDA™, is a new drug being studied for various medical conditions[1][2]. It’s an innovative medication that works in unique ways to help treat different diseases and assist in certain medical procedures.

What Conditions Does Motixafortide Treat?

Motixafortide is being investigated for several conditions:

  • Sickle Cell Disease (SCD): A genetic blood disorder that affects the shape of red blood cells[1][2]
  • Multiple Myeloma: A type of blood cancer that affects plasma cells in the bone marrow[3][5]
  • Pancreatic Cancer: Specifically, pancreatic adenocarcinoma, an aggressive type of pancreatic cancer[4]

How Does Motixafortide Work?

Motixafortide works in several ways:

  1. Stem Cell Mobilization: It helps move stem cells from the bone marrow into the bloodstream. This is crucial for procedures like stem cell collection and transplantation, which are used in treating conditions like sickle cell disease and multiple myeloma[1][2].
  2. CXCR4 Inhibition: Motixafortide is a CXCR4 inhibitor. CXCR4 is a protein found on the surface of some cells. By blocking this protein, motixafortide can affect how cells move and interact, which can be beneficial in treating certain cancers[4].
  3. Enhancing Immunotherapy: In some studies, motixafortide is being tested in combination with immunotherapy drugs. It may help these drugs work better by making the cancer more visible to the immune system[4].

How is Motixafortide Administered?

Motixafortide is typically given as a subcutaneous injection, which means it’s injected just under the skin[1][2]. The dosage and frequency can vary depending on the condition being treated and the specific study protocol. In most trials, the dose is 1.25 mg/kg of body weight[3][5].

Current Clinical Trials

Motixafortide is currently being studied in several clinical trials:

  • Sickle Cell Disease: Studies are looking at how well motixafortide can help mobilize stem cells in patients with SCD. This could potentially lead to new treatments or improve stem cell transplantation procedures[1][2].
  • Multiple Myeloma: Researchers are investigating how motixafortide, when combined with other drugs like G-CSF (a drug that stimulates the bone marrow), can improve stem cell collection for autologous transplantation. This is a procedure where a patient’s own stem cells are used for treatment[3][5].
  • Pancreatic Cancer: A study is testing motixafortide in combination with chemotherapy and immunotherapy to see if it can improve treatment outcomes for patients with metastatic pancreatic cancer[4].

Potential Side Effects

As with any medication, motixafortide may cause side effects. The full range of potential side effects is still being studied in clinical trials. Researchers are carefully monitoring patients for any adverse events. Common side effects observed in clinical trials may include injection site reactions, nausea, or fatigue. However, it’s important to note that side effects can vary depending on the individual and the specific treatment regimen[1][4][5].

It’s crucial to remember that motixafortide is still an experimental drug. While early results are promising, more research is needed to fully understand its effectiveness and safety profile. Patients should always consult with their healthcare providers about the potential risks and benefits of participating in clinical trials or using experimental treatments.

Aspect Details
Primary Conditions Studied Sickle Cell Disease, Multiple Myeloma, Pancreatic Cancer
Main Purpose Stem cell mobilization, Cancer treatment
Administration Method Subcutaneous injection
Common Dosage 1.25 mg/kg
Combination Therapies G-CSF, Natalizumab, Cemiplimab, Gemcitabine, Nab-paclitaxel
Key Outcome Measures CD34+ cell count, Adverse events, Overall response rate, Survival rates
Potential Benefits Improved stem cell collection, Enhanced cancer treatment efficacy
Study Phases Phase 2 and Phase 3 trials

FAQ

  • What is Motixafortide and how does it work? Motixafortide is a drug that acts as a CXCR4 inhibitor. It works by blocking the CXCR4/SDF-1 pathway, which is involved in stem cell mobilization. This action helps to increase the number of stem cells in the bloodstream, making them easier to collect for transplantation or other therapeutic purposes.
  • In which conditions is Motixafortide being studied? Motixafortide is being studied in several conditions, including sickle cell disease, multiple myeloma, and pancreatic cancer. Clinical trials are exploring its potential in stem cell mobilization for transplantation and as part of combination therapies for cancer treatment.
  • How is Motixafortide administered in clinical trials? In most trials, Motixafortide is administered as a subcutaneous injection. The dosage and frequency can vary depending on the specific trial and condition being studied. For example, in some trials, it's given at a dose of 1.25 mg/kg, either as a single dose or multiple doses over several days.
  • What are the potential benefits of using Motixafortide for stem cell mobilization? Motixafortide may help increase the number of stem cells that can be collected for transplantation. This could potentially improve the success rates of stem cell transplants and make the collection process more efficient, requiring fewer apheresis sessions to obtain the necessary number of cells.
  • Are there any known side effects of Motixafortide? While the full safety profile is still being studied, clinical trials are monitoring for potential side effects. Common measures include tracking adverse events, changes in vital signs, and any dose-limiting toxicities. The safety and tolerability of Motixafortide are key aspects being evaluated in these trials.

Ongoing Clinical Trials on Motixafortide

  • Study on the Safety and Effectiveness of Motixafortide and G-CSF for Stem Cell Collection in Patients with Multiple Myeloma

    Not recruiting

    1 1
    Investigated drugs:
    Germany Hungary Italy Spain

Glossary

  • Apheresis: A medical procedure in which blood is drawn from a person and separated into its components, some of which are retained while the remainder is returned to the body. In stem cell collection, it's used to collect stem cells from the bloodstream.
  • CD34+ cells: A type of cell that indicates the presence of hematopoietic stem cells. The number of CD34+ cells is often used as a measure of the effectiveness of stem cell mobilization.
  • CXCR4: A protein on the surface of certain cells that acts as a receptor for the SDF-1 (CXCL12) chemokine. It plays a role in stem cell homing and retention in the bone marrow.
  • G-CSF: Granulocyte Colony-Stimulating Factor, a protein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream.
  • Hematopoietic Stem Cells (HSCs): Immature cells that can develop into all types of blood cells, including white blood cells, red blood cells, and platelets.
  • Mobilization: The process of moving stem cells from the bone marrow into the bloodstream, where they can be more easily collected for transplantation.
  • Multiple Myeloma: A type of blood cancer that affects plasma cells, a type of white blood cell that normally produces antibodies.
  • Pancreatic Adenocarcinoma: The most common type of pancreatic cancer, which starts in the cells that line the ducts of the pancreas.
  • Sickle Cell Disease (SCD): A group of inherited red blood cell disorders where red blood cells become hard and sticky and look like a C-shaped farm tool called a 'sickle'.
  • Stem Cell Transplantation: A procedure in which healthy stem cells are transferred to replace damaged or diseased bone marrow. It can be autologous (using the patient's own cells) or allogeneic (using donor cells).

References

  1. https://clinicaltrials.gov/study/NCT06442761
  2. https://clinicaltrials.gov/study/NCT05618301
  3. https://clinicaltrials.gov/study/NCT06547112
  4. https://clinicaltrials.gov/study/NCT04543071
  5. https://clinicaltrials.gov/study/NCT06514508